

Oxidation-Reduction Condensation of Diazaphosphites for Carbon-Heteroatom Bond Formation Based on Mitsunobu Mechanism

Hai Huang,^{†,‡} Jun Yong Kang^{*,†}

junyong.kang@unlv.edu

[†]Department of Chemistry and Biochemistry, University of Nevada Las Vegas,

4505 S. Maryland Parkway, Las Vegas, NV 89154-4003

[‡] Department of Applied Chemistry, College of Chemistry and Molecular
Engineering, Nanjing Tech University, No. 30 Puzhu Road (S), Nanjing 211816,
People' s Republic of China


Supporting Information

1. General information.....	S2
2. Synthesis of diazaphosphites.....	S3
3. The general procedure for the substitution reaction.....	S8


1. General information.

All reactions were carried out under an argon atmosphere in oven-dried glassware with magnetic stirring bar. Dry solvents (THF, toluene, CH₃CN, Ether and DCM) were obtained by solvent purification system under argon. Morpholine was purchased from Alfa Aesar with a purity of more than 98%. All other commercially available reagents were purchased from Oakwood Chemicals with a purity of more than 98% and used as received without further purification. Purification of reaction products was carried out by flash column chromatography using silica gel 60 (230-400 mesh). Analytical thin layer chromatography was performed on 0.25 mm aluminum-backed silica gel 60-F plates. Visualization was accompanied with UV light and KMnO₄ solution. Concentration under reduced pressure refers to the removal of volatiles using a rotary evaporator attached to a dry diaphragm pump (10-15 mm Hg) followed by pumping to a constant weight with an oil pump (<300 mTorr). Infrared (IR) spectra were recorded on a Shimadzu IRAffinity-1 spectrometer with KBr wafers or a film on KBr plate. High-resolution mass spectra (HRMS) were recorded on a Shimadzu LCMS-IT-TOF mass spectrometer using ESI (electrospray ionization). ¹H NMR spectra were recorded in CDCl₃ on 400 MHz NMR spectrometer (Varian Gemini 400 Hz). The ¹H chemical shifts are referenced to residual solvent signals at δ 7.26 (CHCl₃) or δ 0.00 (TMS). ¹H NMR coupling constants (*J*) are reported in Hertz (Hz) and multiplicities are indicated as follows: s (singlet), bs (broad singlet), d (doublet), t (triplet), m (multiplet), dd (doublet of doublets), dt (doublet of triplets), tt (triplet of triplets). ¹³C NMR spectra were proton decoupled and recorded in CDCl₃ on 100.5 MHz NMR spectrometer. The ¹³C chemical shifts are referenced to solvent signals at δ 77.16 (CDCl₃). ³¹P NMR spectra were proton decoupled and recorded in CDCl₃ on 162 MHz NMR spectrometer. ³¹P chemical shifts are reported relative to 85% H₃PO₄ (0.00 ppm) as an external standard.


2. Synthesis of diazaphosphites




To a solution of 2-chloro-1,3-diphenyl-1,3,2-diazaphospholidine (1.0 equiv) in DCM (0.1 M) were added alcohol (1.0 equiv) and Et₃N (1.5 equiv) at 0 °C. The reaction mixture was allowed to warm up to room temperature and stirred for 2 h. After stirring for 2 h at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was subjected to flash column chromatography on silica gel (gradient eluent of hexanes/ether = 5/1) to give corresponding diazaphosphites **1**.




2-(Benzyloxy)-1,3-diphenyl-1,3,2-diazaphospholidine (1b). White solid; 434.0 mg, 42%; mp 83-84 °C; $R_f = 0.50$ ($v_{\text{hexane}}/v_{\text{ether}} = 5:1$), $v_{\text{hexane}}/v_{\text{ether}}$ (5/1) for column; IR ν (KBr, cm^{-1}) 3028, 2938, 2865, 1600, 1499, 1271, 1213, 1187, 1072, 987; ¹H NMR (400 MHz, CDCl₃) δ 7.32-7.26 (m, 4H), 7.20-7.14 (m, 7H), 7.11-7.08 (m, 2H), 6.93 (tt, $J = 7.2, 1.2$ Hz, 2H), 4.61 (d, $J = 6.8$ Hz, 2H), 3.92-3.86 (m, 2H), 3.86-3.79 (m, 2H); ¹³C NMR (100.5 MHz, CDCl₃) δ 145.0 (d, $J = 17.9$ Hz), 138.0 (d, $J = 2.9$ Hz), 129.3, 128.2, 127.4, 127.3, 120.1 (d, $J = 1.5$ Hz), 115.4 (d, $J = 13.5$ Hz), 65.3, 47.4 (d, $J = 9.7$ Hz); ³¹P NMR (162 MHz, CDCl₃): δ 103.6 ppm. HRMS (ESI): found $[\text{M} + \text{H}]^+$ values corresponding to 2-(benzyloxy)-1,3-diphenyl-1,3,2-diazaphospholidine 2-oxide; calcd for C₂₁H₂₁N₂O₂P ($[\text{M} + \text{H}]^+$): 365.1413; found: 365.1415.




2-((4-Fluorobenzyl)oxy)-1,3-diphenyl-1,3,2-diazaphospholidine (1c). white solid; 235.9 mg, 37%; mp 106-107 °C; $R_f = 0.50$ ($v_{\text{hexane}}/v_{\text{ether}} = 5:1$), $v_{\text{hexane}}/v_{\text{ether}}$ (5/1) for column; **IR** ν (KBr, cm^{-1}) 3024, 2931, 2866, 1597, 1508, 1488, 1284, 1272, 986; **^1H NMR** (400 MHz, CDCl_3) δ 7.29 (t, $J = 8.8$ Hz, 4H), 7.17-7.12 (m, 4H), 7.06-7.00 (m, 2H), 6.94 (t, $J = 7.2$ Hz, 2H), 6.85 (tt, $J = 8.8, 2.0$ Hz, 2H), 4.57 (d, $J = 7.2$ Hz, 2H), 3.91-3.77 (m, 4H); **^{13}C NMR** (100.5 MHz, CDCl_3) δ 162.2 (d, $J = 244.1$ Hz), 144.9 (d, $J = 17.1$ Hz), 133.9 (d, $J =$ Hz), 129.3, 129.1 (d, $J = 8.2$ Hz), 120.2 (d, $J = 1.4$ Hz), 115.4 (d, $J = 13.4$ Hz), 115.1 (d, $J = 21.5$ Hz), 64.6, 47.4 (dd, $J = 9.7$ Hz); **^{31}P NMR** (162 MHz, CDCl_3): δ 104.1 ppm; **HRMS** (ESI): m/z calcd for $\text{C}_{21}\text{H}_{20}\text{FN}_2\text{OP}$ ($[\text{M}+\text{H}]^+$): 367.1370; Found: 367.1360.




2-((4-Chlorobenzyl)oxy)-1,3-diphenyl-1,3,2-diazaphospholidine (1d). White solid; 281.2 mg, 49%; mp 110-111 °C; $R_f = 0.50$ ($v_{\text{hexane}}/v_{\text{ether}} = 5:1$), $v_{\text{hexane}}/v_{\text{ether}}$ (5/1) for column; **IR** ν (KBr, cm^{-1}) 3026, 2925, 2863, 1595, 1488, 1470, 1284, 1272, 988; **^1H NMR** (400 MHz, CDCl_3) δ 7.32-7.25 (m, 4H), 7.16-7.10 (m, 6H), 7.02-6.98 (m, 2H), 6.93 (tt, $J = 7.2, 1.2$ Hz, 2H), 4.57 (d, $J = 7.2$ Hz, 2H), 3.92-3.75 (m, 4H); **^{13}C NMR** (100.5 MHz, CDCl_3) δ 144.9 (d, $J = 17.1$ Hz), 136.6 (d, $J = 2.3$ Hz), 133.2, 129.3, 128.6, 128.3, 120.0, 115.4 (d, $J = 13.4$ Hz), 64.6, 47.4 (d, $J = 9.6$ Hz); **^{31}P NMR** (162 MHz, CDCl_3): δ 104.4 ppm; **HRMS** (ESI): m/z calcd for $\text{C}_{21}\text{H}_{20}\text{ClN}_2\text{OP}$ ($[\text{M}+\text{H}]^+$): 383.1075; Found: 383.1080.




1,3-Diphenyl-2-((4-(trifluoromethyl)benzyl)oxy)-1,3,2-diazaphospholidine (1e). White solid; 395.2 mg, 49%; mp 80-81 °C; $R_f = 0.50$ ($v_{\text{hexane}}/v_{\text{ether}} = 5:1$), $v_{\text{hexane}}/v_{\text{ether}}$ (5/1) for column; **IR** ν (KBr, cm^{-1}) 3062, 3029, 2929, 2855, 1597, 1499, 1329, 1273, 1166, 1116, 1067, 987; **^1H NMR** (400 MHz, CDCl_3) δ 7.40 (d, $J = 8.4$ Hz, 2H), 7.31-7.24 (m, 4H), 7.18 (d, $J = 7.6$ Hz, 2H), 7.15-7.10 (m, 4H), 6.93 (tt, $J = 7.6, 0.8$ Hz, 2H), 4.67 (d, $J = 7.2$ Hz, 2H), 3.92-3.74 (m, 4H); **^{13}C NMR** (100.5 MHz, CDCl_3) δ 144.8 (d, $J = 17.1$ Hz), 142.1, 129.7, 129.3, 127.2, 125.1 (q, $J = 3.8$ Hz), 124.1 (d, $J = 268.0$ Hz), 120.3, 115.4 (d, $J = 14.2$ Hz), 64.5, 47.4 (d, $J = 9.7$ Hz); **^{31}P NMR** (162 MHz, CDCl_3): δ 104.9 ppm; **HRMS** (ESI): m/z calcd for $\text{C}_{22}\text{H}_{20}\text{N}_2\text{OF}_3\text{P}$ ($[\text{M}+\text{H}]^+$): 417.1338; Found: 417.1340.



2-((2,4-Dichlorobenzyl)oxy)-1,3-diphenyl-1,3,2-diazaphospholidine (1f). White solid; 342.7 mg, 55%; mp 76-77 °C; $R_f = 0.50$ ($v_{\text{hexane}}/v_{\text{ether}} = 5:1$), $v_{\text{hexane}}/v_{\text{ether}}$ (5/1) for column; **IR** ν (KBr, cm^{-1}) 3026, 2926, 2862, 1599, 1499, 1472, 1278, 1272, 1117, 1020, 991; **^1H NMR** (400 MHz, CDCl_3) δ 7.30-7.22 (m, 5H), 7.17-7.11 (m, 5H), 7.00 (dd, $J = 8.0, 2.0$ Hz, 1H), 6.93 (tt, $J = 7.2, 1.2$ Hz, 2H), 4.57 (d, $J = 7.2$ Hz, 2H), 3.96-3.75 (m, 4H); **^{13}C NMR** (100.5 MHz, CDCl_3) δ 144.8 (d, $J = 17.8$ Hz), 134.5 (d, $J = 2.3$ Hz), 133.5, 132.6, 129.5, 129.3, 128.7, 127.0, 120.3 (d, $J = 1.5$ Hz), 115.4 (d, $J = 14.1$ Hz), 61.8, 47.5 (d, $J = 9.7$ Hz); **^{31}P NMR** (162 MHz, CDCl_3): δ 104.9 ppm; **HRMS** (ESI): found $[\text{M} + \text{H}]^+$ values corresponding to N^1, N^2 -diphenylethane-1,2-diamine; calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2$ ($[\text{M} + \text{H}]^+$): 213.1386; found: 213.1395.




2-((4-Methylbenzyl)oxy)-1,3-diphenyl-1,3,2-diazaphospholidine (1g). White solid; 181.7 mg, 33%; mp 84-85 °C; $R_f = 0.50$ ($v_{\text{hexane}}/v_{\text{ether}} = 5:1$), $v_{\text{hexane}}/v_{\text{ether}}$ (5/1) for column; **IR** ν (KBr, cm^{-1}) 3034, 2921, 2859, 1599, 1497, 1473, 1276, 1125, 991; **^1H NMR** (400 MHz, CDCl_3) δ 7.31-7.25 (m, 4H), 7.18-7.13 (m, 4H), 7.01-6.95 (m, 4H), 6.92 (tt, $J = 7.6, 0.8$ Hz, 2H), 4.56 (d, $J = 6.4$ Hz, 2H), 3.92-3.77 (m, 4H), 2.26 (s, 3H); **^{13}C NMR** (100.5 MHz, CDCl_3) δ 145.0 (d, $J = 17.8$ Hz), 137.2, 135.0 (d, $J = 3.0$ Hz), 129.3, 128.9, 127.5, 120.1, 115.4 (d, $J = 14.2$ Hz), 65.3, 47.4 (d, $J = 10.4$ Hz); **^{31}P NMR** (162 MHz, CDCl_3): δ 103.4 ppm; HRMS (ESI): found $[\text{M} + \text{H}]^+$ values corresponding to N^1, N^2 -diphenylethane-1,2-diamine; calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2$ ($[\text{M} + \text{H}]^+$): 213.1386; found: 213.1393.




1,3-Diphenyl-2-(1-phenylethoxy)-1,3,2-diazaphospholidine (1h). White solid; 508.6 mg, 47%; mp 95-96 °C; $R_f = 0.50$ ($v_{\text{hexane}}/v_{\text{ether}} = 5:1$), $v_{\text{hexane}}/v_{\text{ether}}$ (5/1) for column; **IR** ν (KBr, cm^{-1}) 3062, 3028, 2975, 2868, 1597, 1496, 1473, 1281, 1058, 922; **^1H NMR** (400 MHz, CDCl_3) δ 7.28-7.22 (m, 2H), 7.20-7.15 (m, 2H), 7.10-7.04 (m, 7H), 6.96-6.87 (m, 3H), 6.84 (tt, $J = 7.2, 1.2$ Hz, 1H), 5.01-4.93 (m, 1H), 3.85 (ddd, $J = 10.0, 6.4, 4.8$ Hz, 1H), 3.76-3.68 (m, 1H), 3.62-3.48 (m, 2H), 1.31 (d, $J = 6.4$ Hz, 3H); **^{13}C NMR** (100.5 MHz, CDCl_3) δ 145.0 (dd, $J = 30.6, 18.6$ Hz), 143.6, 129.2 (d, $J = 1.5$ Hz), 129.0, 128.0, 127.0, 125.4, 119.8 (dd, $J = 6.7, 1.5$ Hz), 115.4 (dd, $J = 33.5, 14.2$ Hz), 72.3, 47.0 (dd, $J = 55.8, 9.6$ Hz), 25.5 (d, $J = 3.0$ Hz); **^{31}P NMR**

(162 MHz, CDCl₃): δ 103.1 ppm; **HRMS** (ESI): m/z calcd for C₂₂H₂₃N₂OP ([M+H]⁺): 363.1621; Found: 363.1627.




2-((4-Chlorobenzyl)oxy)-1,3-diphenyl-1,3,2-diazaphospholidine (1i). White solid; 260.9 mg, 40%; mp 147-148 °C; R_f = 0.50 ($v_{\text{hexane}}/v_{\text{ether}}$ = 4:1), $v_{\text{hexane}}/v_{\text{ether}}/v_{\text{DCM}}$ (20/4/1) for column; **IR** ν (KBr, cm⁻¹) 3062, 3024, 2930, 2851, 1594, 1496, 1275, 1114, 980; **¹H NMR** (400 MHz, CDCl₃) δ 7.27 (t, J = 7.2 Hz, 4H), 7.18-7.12 (m, 6H), 7.11-7.05 (m, 4H), 7.02-6.97 (m, 4H), 6.93 (td, J = 7.2, 0.8 Hz, 2H), 4.08-4.01 (m, 3H), 3.88-3.73 (m, 4H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 145.0 (d, J = 17.9 Hz), 141.5, 129.3, 128.3, 128.2, 126.4, 120.1 (d, J = 1.5 Hz), 115.4 (d, J = 14.1 Hz), 65.9 (d, J = 3.9 Hz), 51.8 (d, J = 2.3 Hz), 47.5 (d, J = 9.7 Hz); **³¹P NMR** (162 MHz, CDCl₃): δ 103.4 ppm; **HRMS** (ESI): m/z calcd for C₂₈H₂₇N₂OP ([M+H]⁺): 439.1934; Found: 439.1925.




2-(Benzo[d][1,3]dioxol-5-ylmethoxy)-1,3-diphenyl-1,3,2-diazaphospholidine (1j). White solid; 164.2 mg, 28%; mp 126-127 °C; R_f = 0.50 ($v_{\text{hexane}}/v_{\text{ether}}$ = 5:1), $v_{\text{hexane}}/v_{\text{ether}}$ (5/1) for column; **IR** ν (KBr, cm⁻¹) 3034, 2906, 2866, 1592, 1499, 1488, 1281, 1250, 1034, 985; **¹H NMR** (400 MHz, CDCl₃) δ 7.31-7.26 (m, 4H), 7.17-7.12 (m, 4H), 6.93 (t, J = 7.2 Hz, 2H), 6.61 (dd, J = 7.6, 0.8 Hz, 1H), 6.55-6.52 (m, 2H), 5.85 (s, 2H), 3.91-3.76 (m, 4H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 147.2 (d, J = 54.3 Hz), 144.9 (d, J = 17.2 Hz), 131.9 (d, J = 3.0 Hz), 129.6,

129.3, 122.3, 120.9, 120.1 (d, $J = 1.5$ Hz), 116.3 (d, $J = 6.0$ Hz), 115.3 (d, $J = 14.1$ Hz); ^{31}P NMR (162 MHz, CDCl_3): δ 103.7 ppm. HRMS (ESI): found $[\text{M} + \text{H}]^+$ values corresponding to N^1, N^2 -diphenylethane-1,2-diamine; calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2$ ($[\text{M} + \text{H}]^+$): 213.1386; found: 213.1381.




2-(Cinnamyloxy)-1,3-diphenyl-1,3,2-diazaphospholidine (1k). White solid; 159.2 mg, 28%; mp 101-103 °C; $R_f = 0.50$ ($v_{\text{hexane}}/v_{\text{ether}} = 5:1$), $v_{\text{hexane}}/v_{\text{ether}}$ (5/1) for column; IR ν (KBr, cm^{-1}) 3057, 3026, 2923, 2869, 1598, 1496, 1280, 1049, 923; ^1H NMR (400 MHz, CDCl_3) δ 7.32-7.26 (m, 4H), 7.25-7.12 (m, 9H), 6.93 (tt, $J = 7.2, 1.2$ Hz, 2H), 6.39 (d, $J = 16.0$ Hz, 1H), 6.01 (dt, $J = 16.0, 5.6$ Hz, 1H), 4.31-4.25 (m, 2H), 3.95-3.89 (m, 2H), 3.89-3.77 (m, 2H); ^{13}C NMR (100.5 MHz, CDCl_3) δ 145.0 (d, $J = 17.9$ Hz), 136.5, 131.7, 129.3, 128.4, 127.6, 126.4, 126.1 (d, $J = 3.0$ Hz), 120.1 (d, $J = 1.5$ Hz), 115.4 (d, $J = 13.4$ Hz), 64.1, 47.3 (d, $J = 10.4$ Hz); ^{31}P NMR (162 MHz, CDCl_3): δ 104.4 ppm; HRMS (ESI): m/z calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{OP}$ ($[\text{M} + \text{H}]^+$): 375.1621; Found: 375.1614.

3. The general procedure for the substitution reaction.




A mixture of diazaphosphites **1** (0.1 mmol), nucleophiles **2** (0.15 mmol), DIAD (26 μL , 0.15 mmol) and DCM (0.5 mL) in a 2 dram vial with a PTFE cap was stirred for 36 h at 40 °C. After stirring for 36 h at 40 °C, the reaction mixture was concentrated under reduced


pressure. The residue was subjected to flash column chromatography on silica gel to give corresponding products **3**.




4-Benzylmorpholine (3a)¹: Pale yellow oil; 16.0 mg, 90%; $R_f = 0.10$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 4:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (5/1, with 1% Et_3N) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.34-7.29 (m, 4H), 7.29-7.23 (m, 1H), 3.71 (t, $J = 4.8$ Hz, 4H), 3.50 (s, 2H), 2.44 (t, $J = 4.4$ Hz, 4H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 137.7, 129.2, 128.2, 127.1, 67.0, 63.5, 53.6.




4-Benzylthiomorpholine (3b)²: Pale yellow oil; 17.9 mg, 93%; $R_f = 0.40$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 3:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (10/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.34-7.28 (m, 4H), 7.26-7.24 (m, 1H), 3.51 (s, 2H), 2.72-2.65 (m, 8H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 138.1, 129.0, 128.2, 127.1, 63.7, 54.9, 28.0.




Ethyl 1-benzylpiperidine-4-carboxylate (3c)³: Pale yellow oil; 19.2 mg, 78%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 3:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (6/1, with 1% Et_3N) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.31 (d, $J = 4.4$ Hz, 4H), 7.28-7.23 (m, 1H), 4.12 (q, $J = 7.2$ Hz, 2H), 3.48 (s, 2H), 2.85 (td, $J = 12.0, 3.2$ Hz, 2H), 2.31-2.23 (m, 1H), 2.02 (dt, $J = 11.2, 4.0$ Hz, 2H), 1.91-1.83 (m, 2H), 1.82-1.70 (m, 2H), 1.24 (t, $J = 7.2$ Hz, 3H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 175.2, 138.4, 129.0, 128.2, 126.9, 63.2, 60.2, 52.9, 41.2, 28.3, 14.2.




tert-Butyl 4-benzylpiperazine-1-carboxylate (3d)⁴: Pale yellow oil; 23.3 mg, 83%; $R_f = 0.20$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 3:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (6/1, with 1% Et_3N) for column; **^1H NMR** (400 MHz, CDCl_3) δ 7.31 (d, $J = 4.4$ Hz, 4H), 7.29-7.23 (m, 1H), 3.51 (s, 2H), 3.42 (t, $J = 4.8$ Hz, 4H), 2.38 (t, $J = 4.8$ Hz, 4H), 1.46 (s, 9H); **^{13}C NMR** (100.5 MHz, CDCl_3) δ 154.8, 137.9, 129.1, 128.2, 127.1, 79.5, 63.0, 52.8, 28.4, 28.3.




1-Benzyl-4-(tert-butyl)piperazine (3e)⁵: Pale yellow oil; 16.5 mg, 72%; $R_f = 0.10$ ($v_{\text{EtOAc}}/v_{\text{MeOH}} = 95:5$), $v_{\text{EtOAc}}/v_{\text{MeOH}}$ (95/5) for column; **^1H NMR** (400 MHz, CDCl_3) δ 7.34-7.27 (m, 4H), 7.27-7.21 (m, 1H), 3.51 (s, 2H), 2.60 (bs, 4H), 2.50 (bs, 4H), 1.46 (s, 9H); **^{13}C NMR** (100.5 MHz, CDCl_3) δ 138.1, 129.3, 128.1, 126.9, 63.1, 53.8, 45.6, 25.9, 21.9.




1-Benzyl-4-cyclohexylpiperazine (3f)⁶: Pale yellow oil; 17.7 mg, 73%; $R_f = 0.10$ ($v_{\text{EtOAc}}/v_{\text{MeOH}} = 98:2$), $v_{\text{EtOAc}}/v_{\text{MeOH}}$ (98/2) for column; **^1H NMR** (400 MHz, CDCl_3) δ 7.31 (d, $J = 4.4$ Hz, 4H), 7.28-7.22 (m, 1H), 3.51 (s, 2H), 2.63 (bs, 4H), 2.53 (bs, 4H), 2.27 (bs, 1H), 1.94-1.76 (m, 4H), 1.65-1.58 (m, 1H), 1.30-1.05 (m, 5H); **^{13}C NMR** (100.5 MHz, CDCl_3) δ 138.0, 129.3, 128.2, 127.0, 63.6, 63.1, 53.3, 48.8, 28.8, 26.2, 25.8.




1-Benzhydryl-4-benzylpiperazine (3g)⁷: White solid; 27.7 mg, 81%; $R_f = 0.40$ ($V_{\text{hexane}}/V_{\text{EtOAc}} = 3:1$), $V_{\text{hexane}}/V_{\text{EtOAc}}$ (9/1-4/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.43-7.37 (m, 4H), 7.30-7.20 (m, 9H), 7.15 (tt, $J = 7.2, 2.0$ Hz, 2H), 4.22 (s, 1H), 3.51 (s, 2H), 2.47 (bs, 4H), 2.42 (bs, 4H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 142.8, 138.1, 129.2, 128.4, 128.1, 128.0, 126.9, 126.8, 76.2, 63.1, 53.3, 51.9.




Tribenzylamine (3h)¹: Pale yellow oil; 23.2 mg, 81%; $R_f = 0.50$ ($V_{\text{hexane}}/V_{\text{EtOAc}} = 8:1$), $V_{\text{hexane}}/V_{\text{EtOAc}}$ (10/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.44-7.36 (m, 6H), 7.36-7.28 (m, 6H), 7.22 (tt, $J = 7.2, 1.2$ Hz, 3H), 3.55 (s, 6H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 139.6, 128.7, 128.2, 126.8, 57.9.




N,N-Dibenzylaniline (3i)⁶: Pale yellow oil; 18.5 mg, 68%; $R_f = 0.05$ ($V_{\text{hexane}}/V_{\text{EtOAc}} = 100:1$), $V_{\text{hexane}}/V_{\text{DCM}}$ (20/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.35-7.29 (m, 4H), 7.27-7.22 (m, 6H), 7.19-7.17 (m, 2H), 6.74 (d, $J = 8.0$ Hz, 2H), 6.70 (t, $J = 7.2$ Hz, 1H), 4.65 (s, 4H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 149.2, 138.6, 129.2, 128.6, 126.8, 126.6, 116.7, 112.4, 54.2.




***N,N*-dibenzyl-4-methylbenzenesulfonamide (3j)**⁸: White solid; 32.6 mg, 93%; $R_f = 0.20$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 10:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (15/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 7.73 (dt, $J = 8.0, 1.6$ Hz, 2H), 7.29 (d, $J = 7.6$ Hz, 2H), 7.23-7.18 (m, 6H), 7.08-7.03 (m, 4H), 4.31 (s, 4H), 2.44 (s, 3H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 143.2, 137.7, 135.7, 129.7, 128.6, 128.4, 127.6, 127.2, 50.5, 21.5.




Dibenzylamine (3k)⁶: Pale yellow oil; 8.8 mg, 45%; $R_f = 0.20$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 4:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (5/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 7.36-7.30 (m, 8H), 7.27-7.23 (m, 2H), 3.81 (s, 4H), 1.61 (s, 1H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 140.4, 128.4, 128.1, 126.9, 53.2.




***N*-Benzylaniline (3l)**⁶: Pale yellow oil; 7.0 mg, 38%; $R_f = 0.40$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 7.39-7.31 (m, 4H), 7.30-7.29 (m, 1H), 7.20-7.19 (m, 2H), 6.71 (tt, $J = 7.2, 1.2$ Hz, 1H), 6.66-6.61 (m, 2H), 4.33 (s, 2H), 4.01 (s, 1H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 148.1, 139.4, 129.3, 128.6, 127.5, 127.2, 117.5, 112.8, 48.3.




N-benzyl-4-methylbenzenesulfonamide (3m)⁹: White solid; 23.4 mg, 90%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 3:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (10/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.77-7.72 (m, 2H), 7.31-7.22 (m, 5H), 7.20-7.17 (m, 2H), 4.88 (t, $J = 6.4$ Hz, 1H), 4.10 (d, $J = 6.4$ Hz, 2H), 2.43 (s, 3H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 143.5, 136.8, 136.3, 129.7, 128.6, 127.9, 127.8, 127.2, 47.2, 21.5.




Benzyl benzoate (4a)¹⁰: Pale yellow oil; 19.0 mg, 90%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 8.10-8.06 (m, 2H), 7.58-7.53 (m, 1H), 7.47-7.31 (m, 7H), 5.37 (s, 2H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 166.4, 136.0, 133.0, 129.7, 128.6, 128.4, 128.2, 128.1, 66.7.




Benzyl 4-methylbenzoate (4b)¹⁰: Pale yellow oil; 21.0 mg, 93%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.97 (d, $J = 8.4$ Hz, 2H), 7.44 (d, $J = 7.2$ Hz, 2H), 7.41-7.30 (m, 3H), 7.23 (d, $J = 8.0$ Hz, 2H), 5.35 (s, 2H), 2.40 (s, 3H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 166.5, 143.7, 136.2, 129.7, 129.1, 128.6, 128.2, 128.1, 127.4, 66.5, 21.6.




Benzyl 4-fluorobenzoate (4c)¹¹: Pale yellow oil; 20.8 mg, 90%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 8.12-8.06 (m, 2H), 7.46-7.32 (m, 5H), 7.14-7.07 (m, 2H), 5.35 (s, 2H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 165.8 (d, $J = 253.0$ Hz), 165.4, 135.9, 132.2 (d, $J = 9.7$ Hz), 128.6, 128.3, 128.2, 126.4 (d, $J = 3.0$ Hz), 115.5 (d, $J = 22.3$ Hz), 66.8.




Benzyl 4-chlorobenzoate (4d)¹⁰: Pale yellow oil; 22.2 mg, 91%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 8.00 (dt, $J = 8.8, 2.0$ Hz, 2H), 7.46-7.32 (m, 7H), 5.35 (s, 2H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 165.6, 139.5, 135.8, 131.1, 128.7, 128.6, 128.5, 128.4, 128.2, 66.9.




Benzyl 4-bromobenzoate (4e)¹⁰: Pale yellow oil; 27.8 mg, 96%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 8.93 (dt, $J = 8.8, 2.0$ Hz, 2H), 7.57 (dt, $J = 8.4, 2.0$ Hz, 2H), 7.45-7.32 (m, 5H), 5.35 (s, 2H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 165.7, 135.8, 131.7, 131.2, 129.0, 128.6, 128.4, 128.2, 128.1, 66.9.




Benzyl 4-nitrobenzoate (4f)¹⁰: White solid; 24.7 mg, 96%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; ¹H NMR (400 MHz, CDCl₃) δ 8.30-8.22 (m, 4H), 7.48-7.34 (m, 5H), 5.41 (s, 2H); ¹³C NMR (100.5 MHz, CDCl₃) δ 164.5, 135.5, 135.2, 130.8, 128.7, 128.6, 128.4, 123.53, 123.52, 67.6.




Benzyl 4-(trifluoromethyl)benzoate (4g)¹⁰: Pale yellow oil; 25.4 mg, 91%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; ¹H NMR (400 MHz, CDCl₃) δ 8.20-8.16 (m, 2H), 7.72-7.68 (m, 2H), 7.47-7.33 (m, 5H), 5.39 (s, 2H); ¹³C NMR (100.5 MHz, CDCl₃) δ 165.2, 135.5, 134.5 (d, $J = 32.7$ Hz), 133.3 (d, $J = 1.5$ Hz), 130.1, 128.7, 128.5, 128.3 (d, $J = 1.5$ Hz), 125.4 (q, $J = 3.7$ Hz), 123.6 (d, $J = 271.6$ Hz), 67.2.




Benzyl 2,4-dichlorobenzoate (4h)¹¹: Pale yellow oil; 26.5 mg, 94%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, $J = 8.4$ Hz, 1H), 7.47 (d, $J = 2.0$ Hz, 1H), 7.46-7.42 (m, 2H), 7.41-7.32 (m, 3H), 7.28 (dd, $J = 8.8, 2.0$ Hz, 1H), 5.36 (s, 2H); ¹³C NMR (100.5 MHz, CDCl₃) δ 164.5, 138.4, 135.3, 135.1, 132.6, 131.0, 128.6, 128.5, 128.4, 128.1, 127.0, 67.4.




Benzyl cinnamate (4i)¹¹: Pale yellow oil; 19.3 mg, 81%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.73 (d, $J = 16.0$ Hz, 1H), 7.53-7.49 (m, 2H), 7.44-7.31 (m, 8H), 6.49 (d, $J = 16.0$ Hz, 1H), 5.25 (s, 2H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 166.8, 145.2, 136.1, 134.4, 130.3, 128.9, 128.6, 128.3, 128.2, 128.1, 117.9, 66.4.




Benzyl cyclohexanecarboxylate (4j)¹¹: Pale yellow oil; 19.9 mg, 92%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.39-7.28 (m, 5H), 5.11 (s, 2H), 2.40-2.30 (m, 1H), 1.97-1.89 (m, 2H), 1.79-1.71 (m, 2H), 1.67-1.60 (m, 1H), 1.52-1.41 (m, 2H), 1.34-1.16 (m, 3H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 175.9, 136.3, 128.5, 128.0, 127.9, 65.9, 43.2, 29.0, 25.7, 25.4.




Benzyl 2,2-diphenylacetate (4k)¹²: White solid; 27.8 mg, 92%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.34-7.23 (m, 15H), 5.18 (s, 2H), 5.07 (s, 1H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 172.3, 138.6, 135.7, 128.6, 128.5, 128.4, 128.2, 128.1, 127.3, 66.9, 57.0.




Benzyl furan-2-carboxylate (4l)¹³: Pale yellow oil; 15.7 mg, 78%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 7.58 (dd, $J = 1.6, 0.8$ Hz, 1H), 7.45-7.43 (m, 2H), 7.41-7.31 (m, 3H), 7.21 (dd, $J = 3.6, 0.8$ Hz, 1H), 7.51-6.49 (m, 1H), 5.34 (s, 2H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 158.5, 146.4, 144.6, 135.6, 128.6, 128.4, 128.3, 118.2, 111.8, 66.5.




(Benzyloxy)benzene (4m)²: Pale yellow oil; 12.2 mg, 66%; $R_f = 0.10$ (v_{hexane}), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 7.44 (d, $J = 7.2$ Hz, 2H), 7.41-7.36 (m, 2H), 7.34-7.26 (m, 3H), 7.00-6.94 (m, 3H), 5.07 (s, 2H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 158.8, 137.1, 129.5, 128.6, 127.9, 127.5, 120.9, 114.8, 69.9.




1-(Benzyloxy)-4-methylbenzene (4n)¹⁴: Colourless oil; 13.3 mg, 67%; $R_f = 0.10$ (v_{hexane}), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 7.42 (d, $J = 7.2$ Hz, 2H), 7.37 (t, $J = 7.2$ Hz, 2H), 7.31 (d, $J = 7.6$ Hz, 1H), 7.08 (d, $J = 8.0$ Hz, 2H), 6.87 (d, $J = 8.8$ Hz, 2H), 5.03 (s, 2H), 2.28 (s, 3H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 156.7, 137.3, 130.2, 129.9, 128.5, 127.9, 127.4, 114.7, 70.1, 20.5.




1-(Benzyloxy)-4-bromobenzene (4o)¹⁴: White solid; 19.7 mg, 75%; $R_f = 0.10$ (v_{hexane}), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.42-7.29 (m, 7H), 6.86-6.81 (m, 2H), 5.02 (s, 2H); $^{13}\text{C NMR}$ (100.5 MHz, CDCl_3) δ 157.9, 136.5, 132.3, 128.6, 128.1, 127.4, 116.7, 113.1, 70.2.




Benzyl(phenyl)sulfane (4p)¹⁵: Pale yellow oil; 6.0 mg, 30%; $R_f = 0.10$ (v_{hexane}), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.32-7.20 (m, 9H), 7.17 (tt, $J = 7.6, 1.2$ Hz, 1H), 4.12 (s, 2H); $^{13}\text{C NMR}$ (100.5 MHz, CDCl_3) δ 137.4, 136.3, 129.8, 128.8, 128.7, 128.5, 127.1, 126.3, 39.0.




Benzyl(4-(tert-butyl)phenyl)sulfane (4q)¹⁶: Colourless oil; 7.4 mg, 29%; $R_f = 0.10$ (v_{hexane}), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.31-7.26 (m, 9H), 4.10 (s, 2H), 1.30 (s, 9H); $^{13}\text{C NMR}$ (100.5 MHz, CDCl_3) δ 149.7, 137.7, 132.9, 129.9, 128.8, 128.5, 127.1, 125.9, 39.4, 34.5, 31.3.




Benzyl(4-fluorophenyl)sulfane (4r)¹⁶: Colourless oil; 7.2 mg, 33%; $R_f = 0.10$ (v_{hexane}), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; ¹H NMR (400 MHz, CDCl₃) δ 7.29-7.18 (m, 7H), 6.93 (tt, $J = 8.8, 2.0$ Hz, 2H), 4.02 (s, 2H); ¹³C NMR (100.5 MHz, CDCl₃) δ 161.1 (d, $J = 245.6$ Hz), 137.5, 133.4 (d, $J = 8.2$ Hz), 130.8, 128.8, 128.5, 127.2, 115.9 (d, $J = 21.5$ Hz), 40.4.




Benzyl(4-(trifluoromethyl)phenyl)sulfane (4s)¹⁷: Colourless oil; 11.0 mg, 41%; $R_f = 0.10$ (v_{hexane}), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, $J = 8.8$ Hz, 2H), 7.37-7.25 (m, 7H), 4.19 (s, 2H); ¹³C NMR (100.5 MHz, CDCl₃) δ 142.0, 136.4, 128.7 (d, $J = 3.8$ Hz), 128.0, 127.6, 127.5, 125.6 (q, $J = 3.7$ Hz), 124.1 (d, $J = 270.2$ Hz), 37.7.




N,N-Dibenzyl-1-(4-fluorophenyl)methanamine (5a)⁶: Pale yellow oil; 25.2 mg, 85%; $R_f = 0.60$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 4:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (50/1) for column; ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.28 (m, 10H), 7.22 (tt, $J = 7.2, 2.4$ Hz, 2H), 6.99 (t, $J = 8.8$ Hz, 2H), 3.53 (s, 4H), 3.50 (s, 2H); ¹³C NMR (100.5 MHz, CDCl₃) δ 161.9 (d, $J = 243.3$ Hz), 139.5, 135.3 (d, $J = 3.0$ Hz), 130.1 (d, $J = 7.4$ Hz), 128.7, 128.2, 126.9, 115.0 (d, $J = 20.9$ Hz), 57.9, 57.1.




***N,N*-Dibenzyl-1-(4-chlorophenyl)methanamine (5b)**¹⁸: Pale yellow oil; 26.3 mg, 82%; $R_f = 0.60$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 4:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (50/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 7.37 (d, $J = 7.2$ Hz, 4H), 7.38-7.30 (m, 5H), 7.29-7.20 (m, 5H), 3.53 (s, 4H), 3.50 (s, 2H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 139.4, 138.2, 132.5, 130.0, 128.7, 128.4, 128.3, 127.0, 57.9, 57.2.




***N,N*-Dibenzyl-1-(4-(trifluoromethyl)phenyl)methanamine (5c)**¹⁹: Pale yellow oil; 28.7 mg, 81%; $R_f = 0.60$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 4:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (50/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 7.54 (dd, $J = 19.2, 8.4$ Hz, 4H), 7.39 (d, $J = 6.8$ Hz, 4H), 7.32 (t, $J = 7.2$ Hz, 4H), 7.26-7.21 (m, 2H), 3.59 (s, 2H), 3.55 (s, 4H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 144.0, 139.1, 129.2 (d, $J = 32.0$ Hz), 128.8, 128.7, 128.3, 127.0, 125.1 (q, $J = 3.7$ Hz), 124.3 (d, $J = 270.2$ Hz), 58.1, 57.4.




***N,N*-Dibenzyl-1-(2,4-dichlorophenyl)methanamine (5d)**²⁰: Pale yellow oil; 28.1 mg, 79%; $R_f = 0.60$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 4:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (50/1) for column; **¹H NMR** (400 MHz, CDCl₃) δ 7.63 (d, $J = 8.0$ Hz, 1H), 7.37 (d, $J = 6.8$ Hz, 4H), 7.33-7.28 (m, 5H), 7.25-7.20 (m, 3H), 3.63 (s, 2H), 3.58 (s, 4H); **¹³C NMR** (100.5 MHz, CDCl₃) δ 139.1, 135.9, 134.5, 132.8, 131.1, 129.0, 128.7, 128.3, 127.1, 127.0, 58.2, 54.1.



4-Methylbenzyl benzoate (5e)²¹: Pale yellow oil; 15.6 mg, 82%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 8.09-8.05 (m, 2H), 7.55 (tt, $J = 6.4, 1.2$ Hz, 1H), 7.45-7.40 (m, 2H), 7.35 (d, $J = 8.0$ Hz, 2H), 7.20 (d, $J = 8.0$ Hz, 2H), 5.33 (s, 2H), 2.36 (s, 3H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 166.5, 138.1, 133.0, 132.9, 130.2, 129.7, 129.2, 128.33, 128.30, 66.6, 21.2.




1-Phenylethyl benzoate (5f)²²: Pale yellow oil; 13.6 mg, 71%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 8.10-8.08 (m, 2H), 7.58-7.52 (m, 1H), 7.47-7.40 (m, 4H), 7.39-7.33 (m, 2H), 7.32-7.24 (m, 1H), 6.14 (q, $J = 6.4$ Hz, 1H), 1.67 (dd, $J = 6.8, 1.6$ Hz, 3H); **¹³C NMR** (100.5 MHz, CDCl_3) δ 165.8, 141.8, 132.9, 130.5, 129.6, 128.5, 128.3, 127.9, 126.0, 72.9, 22.4.




2,2-Diphenylethyl benzoate (5g)²³: Pale yellow oil; 16.8 mg, 58%; $R_f = 0.30$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **¹H NMR** (400 MHz, CDCl_3) δ 7.90 (dd, $J = 8.0, 1.2$ Hz, 2H), 7.52 (tt, $J = 7.6, 1.2$ Hz, 1H), 7.38 (t, $J = 8.0$ Hz, 2H), 7.35-7.28 (m, 8H), 7.26-7.21 (m,

2H), 4.86 (d, $J = 7.6$ Hz, 2H), 4.52 (t, $J = 7.6$ Hz, 1H); ^{13}C NMR (100.5 MHz, CDCl_3) δ 166.4, 141.2, 132.9, 130.1, 129.5, 128.6, 128.3, 128.2, 126.8, 67.2, 49.9.



Cinnamyl benzoate (**5h**) and 1-phenylallyl benzoate (**5h'**) was isolated as a mixture: Pale yellow oil; 11.3 mg, 47% yield; $R_f = 0.35$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 16:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (100/1) for column; **Cinnamyl benzoate (5h)**²⁴: ^1H NMR (400 MHz, CDCl_3) δ 8.13-8.06 (m, 2H), 7.59-7.54 (m, 2H), 7.48-7.40 (m, 2H), 7.38-7.32 (m, 2H), 7.28-7.24 (m, 2H), 6.75 (d, $J = 16.0$ Hz, 1H), 6.40 (dt, $J = 16.4, 6.0$ Hz, 1H), 4.99 (dd, $J = 6.4, 1.2$ Hz, 2H); **1-Phenylallyl benzoate (5h')**²⁵: ^1H NMR (400 MHz, CDCl_3) δ 8.13-8.06 (m, 2H), 7.59-7.54 (m, 1H), 7.48-7.40 (m, 6H), 7.38-7.30 (m, 1H), 6.52 (d, $J = 6.0$ Hz, 1H), 6.13 (ddd, $J = 14.0, 13.2, 5.6$ Hz, 1H), 5.40 (dt, $J = 17.2, 1.6$ Hz, 1H), 5.30 (dt, $J = 10.8, 1.2$ Hz, 1H).



2-(4-(Benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)pyrimidine (Piribedil a)¹: White solid; 16.8 mg, 56%; $R_f = 0.15$ ($v_{\text{hexane}}/v_{\text{EtOAc}} = 2:1$), $v_{\text{hexane}}/v_{\text{EtOAc}}$ (2.5/1, with 2% Et_3N) for column; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (d, $J = 4.4$ Hz, 2H), 6.89 (s, 1H), 6.76 (d, $J = 0.4$ Hz, 2H), 6.46 (t, $J = 4.8$ Hz, 1H), 5.95 (s, 2H), 3.82 (t, $J = 4.8$ Hz, 4H), 3.45 (s, 2H), 2.48 (t, $J = 5.2$ Hz, 4H); ^{13}C NMR (100.5 MHz, CDCl_3) δ 161.6, 157.7, 157.6, 147.6, 146.6, 131.9, 122.2, 109.7, 109.5, 107.9, 100.9, 62.8, 52.8, 43.7.

Reference

1. Hamid, M. H. S. A.; Allen, C. L.; Lamb, G. W.; Maxwell, A. C.; Maytum, H. C.; Watson, A. J. A.; Williams, J. M. J., *J. Am. Chem. Soc.* **2009**, *131*, 1766-1774.
2. Long, T. R.; Maity, P. K.; Samarakoon, T. B.; Hanson, P. R., *Org. Lett.* **2010**, *12*, 2904-2907.
3. O'Brien, C. J.; Nixon, Z. S.; Holohan, A. J.; Kunkel, S. R.; Tellez, J. L.; Doonan, B. J.; Coyle, E. E.; Lavigne, F.; Kang, L. J.; Przeworski, K. C., *Chem. Eur. J.* **2013**, *19*, 15281-15289.
4. Kovalenko, O. O.; Volkov, A.; Adolfsson, H., *Org. Lett.* **2015**, *17*, 446-449.
5. McDermott, B. P.; Campbell, A. D.; *Synlett* **2008**, *2008*, 875-879.
6. Du, Y.; Oishi, S.; Saito, S., *Chem. Eur. J.* **2011**, *17*, 12262-12267.
7. Borukhova, S.; Noël, T.; Hessel, V., *ChemSusChem* **2016**, *9*, 67-74.
8. Lai, J.; Chang, L.; Yuan, G., *Org. Lett.* **2016**, *18*, 3194-3197.
9. Zhu, M.; Fujita, K.-i.; Yamaguchi, R., *Org. Lett.* **2010**, *12*, 1336-1339.
10. Li, Y.; Du, W.; Deng, W.-P., *Tetrahedron* **2012**, *68*, 3611-3615.
11. Finney, E. E.; Ogawa, K. A.; Boydston, A. J., *J. Am. Chem. Soc.* **2012**, *134*, 12374-12377.
12. Carle, M. S.; Shimokura, G. K.; Murphy, G. K., *Eur. J. Org. Chem.* **2016**, *2016*, 3930-3933.
13. Green, R. A.; Pletcher, D.; Leach, S. G.; Brown, R. C. D., *Org. Lett.* **2015**, *17*, 3290-3293.
14. Wang, H.; Ma, Y.; Tian, H.; Yu, A.; Chang, J.; Wu, Y., *Tetrahedron* **2014**, *70*, 2669-2673.
15. Rostami, A.; Rostami, A.; Ghaderi, A., *J. Org. Chem.* **2015**, *80*, 8694-8704.
16. Li, Y.; Pu, J.; Jiang, X., *Org. Lett.* **2014**, *16*, 2692-2695.
17. Ham, J.; Yang, I.; Kang, H., *J. Org. Chem.* **2004**, *69*, 3236-3239.
18. Blondiaux, E.; Cantat, T., *Chem. Commun.* **2014**, *50*, 9349-9352.
19. Dombray, T.; Helleu, C.; Darcel, C.; Sortais, J.-B., *Adv. Synth. Catal.* **2013**, *355*, 3358-3362.
20. Unsalan, S.; Ulgen, M., *FABAD Farmasotik Bilimler Dergisi* **1997**, *22*, 103-109.
21. Zhang, C.; Feng, P.; Jiao, N., *J. Am. Chem. Soc.* **2013**, *135*, 15257-15262.
22. Squitieri, R. A.; Shearn-Nance, G. P.; Hein, J. E.; Shaw, J. T., *J. Org. Chem.* **2016**, *81*, 5278-5284.
23. Lim, S.; Ji, M.; Wang, X.; Lee, C.; Jang, H.-Y., *Eur. J. Org. Chem.* **2015**, *2015*, 591-595.
24. Correia, R.; DeShong, P., *J. Org. Chem.* **2001**, *66*, 7159-7165.
25. Stanley, L. M.; Bai, C.; Ueda, M.; Hartwig, J. F., *J. Am. Chem. Soc.* **2010**, *132*, 8918-8920.